Galapagos NV

-0.36% €27.62

17:30 – 14/03/2026

Nieuws van Galapagos NV

Galapagos Q4 Earnings Call Highlights

Bron: MarketBeat

Autheur: MarketBeat

Gepubliceerd op: 2026-02-24

Galapagos (NASDAQ:GLPG) executives used the company’s year-end 2025 financial results call to outline a strategic reset centered on business development…

Galapagos ontvangt transparantieverklaring van Bank of America

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2026-02-16

Mechelen, België; 16 februari 2026, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft een transparantieverklaring ontvangen van Bank of America.

Galapagos creëert nieuw inschrijvingsrechtenplan

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2026-03-06

Mechelen, België; 6 maart 2026, 22.01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 1.750.000 inschrijvingsrechten heeft gecreëerd onder een nieuw inschrijvingsrechtenplan.

Galapagos Creates New Subscription Right Plan

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2026-03-06

Mechelen, Belgium; March 6, 2026, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under a new subscription right plan.

Galapagos ontvangt transparantieverklaringen van Bank of America

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2026-03-10

Mechelen, België; 10 maart 2026, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) heeft transparantieverklaringen ontvangen van Bank of America.

Galapagos Receives Transparency Notification from Bank of America

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2026-02-16

Mechelen, Belgium; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America.

Galapagos Receives Transparency Notifications from Bank of America

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2026-03-10

Mechelen, Belgium; March 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.

Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2026-02-23

Mechelen, Belgium; February 23, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the full year 2025 and provided an update on the fourth quarter 2025 and its year-to-date performance.

Galapagos rapporteert resultaten over het gehele jaar 2025 en geeft een business update over het vierde kwartaal

Bron: GlobeNewswire

Autheur: Galapagos NV

Gepubliceerd op: 2026-02-23

Mechelen, België; 23 februari 2026, 22:01 CET; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG), rapporteerde vandaag haar financiële resultaten voor het volledige jaar 2025 en gaf een update over het vierde kwartaal 2025 en haar prestatie…

JAK Inhibitors Competitive Landscape Report 2026: Comprehensive Insights on 40+ Companies and 45+ Drugs by Company, Product Type, Development Stage, Administration Route, Molecule Type

Bron: GlobeNewswire

Autheur: Research and Markets

Gepubliceerd op: 2026-02-18

The JAK inhibitors market offers significant opportunities in treating autoimmune and rheumatic diseases through diverse product development by over 40 companies and 45 drugs. Key areas include rheumatoid arthritis, psoriasis, and inflammatory bowel diseases,…

Chronic Kidney Disease Market Competitive Landscape Report 2026: Comprehensive Insights About 75+ Companies and 95+ Drugs by Product Type, Stage, Route of Administration, and Molecule Type

Bron: GlobeNewswire

Autheur: Research and Markets

Gepubliceerd op: 2026-03-03

The chronic kidney disease market is ripe with opportunities for innovative therapies, with over 95 drugs in development and significant research on therapeutic avenues like AMPK activators, SGLT2 inhibitors, and microRNA targeting. Key collaborations and adv…

$3.9 Bn Vaccine Contract Manufacturing Markets, 2026-2036: Growing Outsourcing as a Core Model in Vaccine Contract Manufacturing – Opportunities in New Vaccine Technology and Gene Based Vaccines

Bron: GlobeNewswire

Autheur: Research and Markets

Gepubliceerd op: 2026-02-18

The vaccine contract manufacturing market offers growth opportunities through increased outsourcing, driven by the need for operational agility and cost efficiency amid rising regulatory challenges. Market segmentation spans vaccine types, processes, and glob…

Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline Value

Bron: GlobeNewswire

Autheur: Research and Markets

Gepubliceerd op: 2026-03-12

This report is tailored for C-level executives, business development professionals, licensing managers, legal advisors, and anyone involved in pharmaceutical and biotechnology deal-making. It provides the tools needed to evaluate and negotiate royalty terms e…

Pagina’s

Social Media

Instagram

AEX

AMX

AScX

De Slimme Beleggers

Gemaakt door beleggers voor beleggers